MedinCell S.A.

MedinCell S.A. is a French biopharmaceutical company dedicated to enhancing global health through the development of innovative long-acting injectable treatments. Headquartered in Jacou, France, the company's core mission is to improve treatment adherence and accessibility while minimizing the environmental impact of pharmaceuticals. MedinCell focuses on creating therapeutic solutions that address critical medical challenges worldwide.

The company's proprietary BEPO® technology platform is central to its operations, enabling the controlled and prolonged release of active pharmaceutical ingredients for days, weeks, or months from a single subcutaneous injection. This technology underpins a diverse pipeline of product candidates across various therapeutic areas, including psychiatry, pain management, contraception, and infectious disease prevention. Its key commercial product, UZEDY® (risperidone LAI), approved by the FDA in April 2023 and marketed by Teva Pharmaceuticals, is used for the treatment of schizophrenia and bipolar I disorder. The pipeline also includes mdc-TJK (olanzapine LAI) for schizophrenia and mdc-CWM (celecoxib LAI) for post-operative pain, both in Phase 3 clinical trials, as well as preclinical programs like mdc-WWM for contraception and mdc-STM for malaria.

Led by CEO Christophe Douat, MedinCell is actively expanding its market presence and pipeline. Recent notable developments include UZEDY® achieving $63 million in net sales in Q1 2026, a 62% year-on-year increase, and the FDA's acceptance of Teva's New Drug Application for Olanzapine Extended-Release Injectable Suspension in February 2026. The company successfully completed a €48 million private placement in March 2026 to support its growth strategy and has established strategic collaborations with major pharmaceutical companies like Teva Pharmaceuticals and AbbVie, as well as foundations such as the Bill & Melinda Gates Foundation. MedinCell is positioned as an emerging leader in the long-acting injectable therapeutics market, aiming to redefine treatment standards globally.